New Phototherapy Device to Treat Patients With Crigler-Najjar Disease

NCT ID: NCT02356978

Last Updated: 2017-09-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2017-12-31

Brief Summary

Evaluating the efficacity of a new device phototherapy by comparing it with conventional phototherapy. Jaundice occurs in many newborns, and is, in most cases benign, However, owing to the potential neurotoxicity of unconjugated bilirubin, newborns must be monitored to identify those who might develop severe hyperbilirubinemia an, in rare cases, acute bilirubin encephalopathy or kernicterus. Treatment of jaundice in newborn relies on phototherapy, exposing their skin to light of a specific wavelength . Fluorescent tubes or halogen lamps have been used as light sources for phototherapy for many years. Light-emitting diodes (LEDs) are more recent sources which are power efficient, have a longer life and are portable with low heat production. Several technologies and devices are developed using LEDs and specially a compact system.

Detailed Description

Crigler-Najjar (CN) syndrome is a congenital inborn error of hepatic bilirubin metabolism caused by the deficiency of bilirubin uridinediphosphate glucuronosyltransferase activity CN patients are at permanent risk of life-threatening bilirubin encephalopathy (kernicterus). Treatment of CN disease relies on daily prolonged phototherapy (10-12 h/day). To date, liver transplantation is the only curative treatment available. To date, no phototherapy device exists for teenagers and adults. CN patients use homemade systems or add several neonatal systems together to reach a better efficacy.

A new device has been designed by weaving optical fibers into a sheet connected to LEDs. This new technology, marketed by several manufacturers of phototherapy devices, is used in pediatric wards for treating jaundiced newborns. A prototype of 80× 100cm was thus developed, which combines numerous advantages : important surface of treatment, easy use and transportation, user-friendliness.

Before going to a therapeutic trial for assessing the benefits of this new device in ambulatory current practice, it is essential to make sure of both its feasibility and efficiency on the control of bilirubinemia, under medical supervision.

Hypothesis: the new phototherapy sheet is as effective as, and better tolerated than the usual devices used in CN patients.

Conditions

Crigler Najjar Syndrome; Children

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1

Each patient will be treated before using the active usual homemade device, and after using the experimental new "DRAP" device.

This new sheet was designed by weaving optical fibers connected to LEDs ( "BROCHIER" Technology). The "LIGHTEX" technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)

Group Type: EXPERIMENTAL

Arm1 homemade phototherapy treatment

Intervention Type: DEVICE

session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the "DRAP" device during the next nights.

DRAP

Intervention Type: DEVICE

Interventions

Arm1 homemade phototherapy treatment

session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the "DRAP" device during the next nights.

Intervention Type: DEVICE

DRAP

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• genetic diagnosis of Crigler Najjar disease
• child whose height is between 60cm and 100cm
• patients with follow-up in reference center,

Exclusion Criteria

• opposition of parents
• no social security insurance

• Maximum Eligible Age: 6 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

VINCENT GAJDOS, Professor

Role: PRINCIPAL_INVESTIGATOR

AP-HP, Antoine Béclère Hospital

Locations

AP-HP, Antoine Béclère Hospital

Clamart, , France

Site Status: RECRUITING

Countries

France

Central Contacts

VINCENT GAJDOS, Professor

Role: CONTACT

vincent.gajdos@abc.aphp.fr

+33 1 45 37 42 72

Facility Contacts

VINCENT GAJDOS, Professor

Role: primary

vincent.gajdos@abc.aphp.fr

+33 1 45 37 42 72

Other Identifiers

P140202

Identifier Type: -

Identifier Source: org_study_id